Barclays PLC Gritstone Bio, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 7,101 shares of GRTS stock, worth $213. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,101

Previous 7,101 -0.0%

Holding current value

$213

Previous $4,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$0.45 - $0.71 $14,259 - $22,497	-31,687 Reduced 81.69%	7,101 $4,000
Q2 2024 Aug 14, 2024	SELL	$0.62 - $2.35 $38,147 - $144,593	-61,529 Reduced 61.33%	38,788 $24,000
Q1 2024 May 15, 2024	SELL	$1.96 - $2.9 $81,281 - $120,263	-41,470 Reduced 29.25%	100,317 $258,000
Q4 2023 Feb 15, 2024	BUY	$1.28 - $2.85 $134,453 - $299,369	105,042 Added 285.87%	141,787 $289,000
Q3 2023 Nov 07, 2023	SELL	$1.19 - $2.26 $2,281 - $4,332	-1,917 Reduced 4.96%	36,745 $62,000
Q2 2023 Aug 03, 2023	SELL	$1.66 - $3.03 $56,461 - $103,059	-34,013 Reduced 46.8%	38,662 $75,000
Q1 2023 May 04, 2023	BUY	$2.13 - $3.74 $100,706 - $176,827	47,280 Added 186.18%	72,675 $202,000
Q4 2022 Feb 13, 2023	BUY	$2.17 - $3.92 $368 - $666	170 Added 0.67%	25,395 $88,000
Q3 2022 Nov 03, 2022	BUY	$2.46 - $4.75 $7,079 - $13,670	2,878 Added 12.88%	25,225 $64,000
Q2 2022 Aug 12, 2022	SELL	$1.77 - $4.34 $12,970 - $31,803	-7,328 Reduced 24.69%	22,347 $54,000
Q1 2022 May 16, 2022	SELL	$4.03 - $12.19 $179,467 - $542,857	-44,533 Reduced 60.01%	29,675 $123,000
Q4 2021 Feb 14, 2022	BUY	$8.76 - $13.71 $331,154 - $518,279	37,803 Added 103.84%	74,208 $954,000
Q3 2021 Nov 09, 2021	BUY	$6.41 - $13.54 $80,374 - $169,778	12,539 Added 52.54%	36,405 $393,000
Q2 2021 Aug 13, 2021	SELL	$8.13 - $10.2 $404,646 - $507,674	-49,772 Reduced 67.59%	23,866 $218,000
Q1 2021 May 13, 2021	BUY	$4.07 - $27.11 $259,971 - $1.73 Million	63,875 Added 654.26%	73,638 $694,000
Q4 2020 Feb 11, 2021	SELL	$2.57 - $4.22 $10,454 - $17,166	-4,068 Reduced 29.41%	9,763 $38,000
Q3 2020 Nov 12, 2020	SELL	$2.63 - $8.09 $6,714 - $20,653	-2,553 Reduced 15.58%	13,831 $37,000
Q2 2020 Aug 12, 2020	BUY	$5.69 - $8.17 $46,208 - $66,348	8,121 Added 98.28%	16,384 $109,000
Q1 2020 May 13, 2020	SELL	$5.47 - $11.3 $92,787 - $191,681	-16,963 Reduced 67.24%	8,263 $48,000
Q4 2019 Feb 10, 2020	BUY	$7.07 - $11.61 $85,971 - $141,177	12,160 Added 93.07%	25,226 $225,000
Q3 2019 Nov 14, 2019	SELL	$8.45 - $12.28 $26,980 - $39,210	-3,193 Reduced 19.64%	13,066 $112,000
Q2 2019 Aug 14, 2019	SELL	$9.2 - $15.7 $34,417 - $58,733	-3,741 Reduced 18.71%	16,259 $181,000
Q1 2019 May 15, 2019	BUY	$9.97 - $18.96 $155,990 - $296,648	15,646 Added 359.35%	20,000 $266,000
Q4 2018 Feb 14, 2019	SELL	$11.61 - $31.1 $65,550 - $175,590	-5,646 Reduced 56.46%	4,354 $67,000
Q3 2018 Nov 14, 2018	BUY	$14.24 - $14.24 $142,400 - $142,400	10,000 New	10,000 $142,000

Others Institutions Holding GRTS

# of Institutions

Shares Held

35.4M

Call Options Held

395K

Put Options Held

132K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account